-

12:14:04 PM

ADMP Stock News

ADMP - Adamis Pharmaceuticals Corp

11/23/21 2:39 PM

Nasdaq : ADMP

Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it has received a letter from the

RHEA-AI

neutral

11/22/21 4:47 PM

Nasdaq : ADMP

earnings

Adamis Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and

RHEA-AI

neutral

11/19/21 3:34 PM

Nasdaq : ADMP

earnings

Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor

RHEA-AI

neutral

10/18/21 7:30 AM

Nasdaq : ADMP

fda approval

Adamis Receives FDA Approval for ZIMHI

Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has approved Adamis’ ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL

RHEA-AI

positive

10/04/21 7:30 AM

Nasdaq : ADMP

management

Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors

Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the appointment of Meera J. Desai, Ph.D., as a new director and member of the

RHEA-AI

neutral

09/02/21 7:30 AM

Nasdaq : ADMP

clinical trialcovid-19

Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19

Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the initiation of patient dosing in the Phase 2/3 clinical trial for Tempol, an oral antiviral product candidate, in adult patients with confirmed COVID-19 infection. In preclinical

RHEA-AI

neutral

08/24/21 4:05 PM

Nasdaq : ADMP

management

Adamis Announces Appointment of David C. Benedicto as Chief Financial Officer and Other Events

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that David C. Benedicto, who has been serving as the Company’s Chief Accounting Officer, will succeed Robert O. Hopkins as Chief Financial Officer, effective immediately. Mr. Hopkins is

RHEA-AI

very positive

08/24/21 7:30 AM

Nasdaq : ADMP

covid-19

Adamis Pharmaceuticals Announces a Publication with the Human Immune Monitoring Center at Stanford Demonstrating Tempol Significantly Inhibited Multiple Cytokines from COVID-19 Patient’s Cells

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced a publication in the peer

RHEA-AI

neutral

08/19/21 7:30 AM

Nasdaq : ADMP

covid-19

Adamis Highlights National Institutes of Health (NIH) Article Entitled, “Tempol: A Potential Home Treatment for COVID-19”

Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today highlighted that the NIH has identified Tempol as a potential home treatment

RHEA-AI

neutral

08/04/21 4:05 PM

Nasdaq : ADMP

Adamis Announces Agreement to Sell Portion of US Compounding Business

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has entered into a definitive agreement to sell a

RHEA-AI

neutral

ADMP Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.adamispharmaceuticals.com
CeoDennis Carlo
Security nameAdamis Pharmaceuticals Corp
Issue typecs
SectorManufacturing
Sic code2834
Employees130
Tags
- Health Technology
- Pharmaceuticals: Other
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address11682 El Camino Real Ste 300
StateCalifornia
CitySan Diego
Zip92130
CountryUS
Phone18589972400

ADMP Description:

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The company's SYMJEPI (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis' naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose is currently under FDA review. Adamis is developing additional products, including treatments for acute respiratory diseases, such as COVID-19, influenza, asthma, and COPD. The company's subsidiary, US Compounding Inc., compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use by hospitals, clinics, surgery centers, and vet clinics throughout most of the United States. Forward Looking Statements